Three Possible Scenarios for MFN Implementation in the US: What Can Pharma Expect and What Are the Possible Strategies to Protect Revenue
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
$4995
Just over a year ago, US President Donald Trump signaled his intent to introduce international reference pricing (IRP) for medicines in the US through the May 2025 Most Favored Nation (MFN) executive order. Based on GlobalData's extensive repository of IRP knowledge and daily tracking of pricing and reimbursement developments around the world, in this strategic report GlobalData explores alternative scenarios for MFN implementation and what these mean for the pharmaceutical industry, with a particular focus on how to protect pharma revenue under the different scenarios.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
See what our customers are saying
Related reports
View more Product Type reports
New
New
New